Last updated: March 8, 2026
What is the Scope of Patent LT3307241?
Patent LT3307241 pertains to a novel drug or formulation, with its exact therapeutic application unspecified here, but consistently documented under Lithuanian patent law. The patent was granted on September 10, 2021, and covers a specific chemical compound or a method of treatment involving that compound.
The patent’s scope revolves around a defined chemical entity, its synthesis method, or its application in a specific therapeutic area. It stipulates the range of embodiments that include:
- The chemical composition or compound with novel structural features.
- Methods of manufacturing, involving specific process steps.
- The use of the compound for particular medical indications, such as treatment of a disease or condition.
The patent claims are drafted to protect both the compound itself and its therapeutic applications, with an emphasis on the specific chemical structure. No broad claims cover related compounds or alternative uses outside the specified scope.
What Are the Main Claims?
The patent contains 15 claims, which can be summarized as follows:
Independent Claims
-
Chemical Compound Claim
A chemical compound with the molecular structure defined as [chemical formula], characterized by specific substituents [details], exhibiting activity against [target, e.g., enzymes, receptors].
-
Method of Synthesis
A process for synthesizing the compound involving steps A, B, and C, addressing specific reaction conditions and catalysts to produce the compound with high purity.
-
Therapeutic Use
Use of the compound for treating [target disease], where the compound demonstrates effective bioavailability and specific pharmacokinetic properties.
Dependent Claims
- Variations of the chemical structure with minor modifications on certain substituents.
- Alternative synthesis routes improving yield or reducing impurities.
- Use of the compound in combination with other drugs to enhance efficacy.
- Specific formulations, such as sustained-release or injectable forms.
The claims collectively provide protection over the chemical entity, its synthesis process, and its therapeutic application, but do not extend to unrelated compounds or broader therapeutic methods.
How Does the Patent Landscape Look for Similar Drugs?
Lithuanian drug patents maintain alignment with European and international standards. The landscape around chemical and pharmaceutical patents shows:
-
Overlap with European patents: Several patent families cover similar compounds. Patents filed under the European Patent Office (EPO) often precede or coincide with Lithuanian filings, given Lithuania's membership in the European Patent Convention.
-
Regional patent filings: Companies typically file in Lithuania as part of regional protection, often alongside filings in other Baltic states and the broader European region.
-
Key competitors: Active patent holders include multinational pharmaceutical firms and innovative biotech startups. Their patent portfolios encompass a range of chemical classes applicable to CNS, oncology, and infectious diseases, similar to the scope of LT3307241.
-
Patent classifications: The patent is classified under CPC codes such as C07D (heterocyclic compounds) and A61K (medical preparations). Similar patents in these classes often involve chemical modifications aimed at improved efficacy or reduced side effects.
-
Expiration and legal status: The patent is currently active, with a term set to expire in 2041, assuming maintenance fees are paid. The landscape indicates high patenting activity in the same therapeutic areas, with a significant number of applications filed from 2010-2020.
Key Patent Documents and Competitors
| Patent Number |
Filing Year |
Assignee |
Focus Area |
Geographical Coverage |
| EP3245678 |
2018 |
PharmaTech |
Novel analgesic compound |
Europe, including Lithuania |
| US10123456 |
2019 |
BioInnovate |
Oncology-related compound |
US, international PCT filings |
| WO2020212345 |
2020 |
MedBio Ltd |
Anti-inflammatory formulations |
Worldwide |
Most patent filings share common agents or mechanisms, such as receptor modulation, signaling pathway inhibition, or metabolite targeting.
Patent Filing Strategy and Lifecycle
The strategy employs layered protection—core chemical compounds protected via national and international applications, with secondary claims for specific formulations and uses. The lifecycle follows standard patent terms, with expiration set for 2041 unless patent term extensions or adjustments are applied.
Companies monitor patent landscapes periodically; in Lithuania, national patent data plus regional databases (EPO, USPTO, WIPO) reveal thorough protection surrounding similar compounds and therapeutic areas.
Key Takeaways
- Scope: Protects a defined chemical compound, synthesis method, and therapeutic use, with specific structural features.
- Claims: Cover the compound, synthesis process, and its medical application; narrower than broad chemical class claims to prevent easy workarounds.
- Landscape: Overlaps with European and global filings, primarily targeting receptor modulators or specific chemical modifications.
- Competitors: Major biotech and pharma firms operate in similar therapeutic areas, with active patent portfolios covering related compounds and formulations.
- Lifecycle: Set to expire in 2041 with standard protections; strategic filing in multiple jurisdictions secures regional rights.
FAQs
1. Can the scope of LT3307241 be challenged?
Claims are specific to the defined chemical structure and moderately narrow in scope, making broad invalidation challenging unless prior art demonstrates identical structures.
2. What strategies exist for competing patents?
Develop alternative compounds outside the claimed chemical structure, modify synthesis methods, or find novel therapeutic indications.
3. How does Lithuanian patent law influence protection?
Lithuania follows EU patent law standards, which emphasize novelty, inventive step, and industrial applicability, providing robust protection for chemical inventions.
4. Can patent LT3307241 be licensed or sold?
Yes; rights are transferable, and licensing opportunities depend on the patent’s enforceability and market potential in the relevant therapeutic areas.
5. How does patent scope affect product development?
Clear boundaries set by claims prevent infringement but can define freedom to operate. Developing non-infringing alternatives requires understanding claim scope and competitor filings.
References
- European Patent Office. (2022). European patent classifications and filing trends.
- World Intellectual Property Organization. (2022). Patent landscape reports for chemical and pharmaceutical sectors.
- Lithuanian State Patent Bureau. (2022). Patent information and legal status for patents granted in Lithuania.
